<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331067</url>
  </required_header>
  <id_info>
    <org_study_id>202007016</org_study_id>
    <nct_id>NCT04331067</nct_id>
  </id_info>
  <brief_title>Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer</brief_title>
  <official_title>Phase Ib/II Study to Evaluate Safety and Tolerability of Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that the combination of cabiralizumab and nivolumab with&#xD;
      neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor&#xD;
      infiltrating lymphocytes (TIL) compared to neoadjuvant chemotherapy plus nivolumab in&#xD;
      patients with early stage triple-negative breast cancer (TNBC) and improve clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in tumor infiltrating lymphocytes (TILs)</measure>
    <time_frame>Baseline to after initiation of therapy (4 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in tumor associated macrophages</measure>
    <time_frame>Baseline to after initiation of therapy (4 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the regimen as measured by incidence of adverse events (safety lead-in only)</measure>
    <time_frame>From start of treatment through 100 days after last infusion of nivolumab and/or cabiralizumab or surgery whichever occurs first (approximately 16 weeks)</time_frame>
    <description>-The first six patients randomized to each arm will be part of a safety run-in.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR)</measure>
    <time_frame>At time of surgery (estimated to be 12 weeks)</time_frame>
    <description>-A pathologic complete response (pCR) is defined as no histology evidence of invasive tumor cells in the surgical breast specimen and sentinel or axillary lymph nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival (RFS)</measure>
    <time_frame>Through completion of follow-up (estimated to be 15 months)</time_frame>
    <description>-RFS is defined from time of surgery to the earliest time of recurrence, time to development of a second cancer, or time to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the combination of nivolumab +/- cabiralizumab + neoadjuvant chemotherapy as measured by rate of grade 3 or higher adverse events related to the study drugs</measure>
    <time_frame>From start of treatment through 100 days after last infusion of nivolumab and/or cabiralizumab or surgery whichever occurs first (approximately 16 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>-Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy consists of paclitaxel and carboplatin. Paclitaxel will be given intravenously (IV) at a dose of 80 mg/m^2 on a weekly basis for 12 weeks. Carboplatin will be given IV at a dose of AUC 5 every 3 weeks for 12 weeks. Nivolumab will be given IV at a dose of 240 mg every 2 weeks for 12 weeks. Nivolumab will be administered first, followed by carboplatin, followed by paclitaxel.&#xD;
Cabiralizumab will be given IV at a dose of 4 mg/kg every 2 weeks for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>-Given standard of care</description>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>-Given standard of care</description>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>-Given standard of care</description>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cabiralizumab</intervention_name>
    <description>-Will be provided by Bristol Myers Squibb</description>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
    <other_name>BMS-986227</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsy</intervention_name>
    <description>-Baseline, week 5, surgery, and at time of relapse (optional)</description>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow</intervention_name>
    <description>-Time of port placement (baseline), time of surgery, and time of recurrence (optional)</description>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>-Baseline, week 5, prior to surgery , and disease progression (optional)</description>
    <arm_group_label>Arm A: Neoadjuvant chemo + nivolumab</arm_group_label>
    <arm_group_label>Arm B: Neoadjuvant chemo + nivolumab + cabiralizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed newly diagnosed ER-/HER2- breast cancer. ER&#xD;
             and PR &lt; Allred score of 3 or &lt; 1% positive staining cells in the invasive component&#xD;
             of the tumor. HER2 negative by FISH or IHC staining 0 or 1+ according to NCCN&#xD;
             guidelines.&#xD;
&#xD;
          -  Clinical stage II or III (by AJCC 8th edition at least T2, any N, M0 or if N+ then any&#xD;
             T) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision&#xD;
             of the breast cancer after neoadjuvant therapy as the treatment goal.&#xD;
&#xD;
          -  Tumor size at least 2 cm in one dimension by clinical or radiographic exam (WHO&#xD;
             criteria). Patients with histologically confirmed or clinically palpable lymph nodes&#xD;
             may be enrolled regardless of tumor size. A palpable mass is not required as long as&#xD;
             the mass is at least 2 cm in one dimension by radiographic exam. 2D measurements&#xD;
             should be completed during screening if available.&#xD;
&#xD;
          -  No prior therapy for this disease&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Normal bone marrow and organ function as defined below:&#xD;
&#xD;
               -  Leukocytes ≥ 2,000/mcL (stable off any growth factor within 4 weeks of first&#xD;
                  study treatment administration)&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mcL (stable off any growth factor within 4&#xD;
                  weeks of first study treatment administration)&#xD;
&#xD;
               -  Platelets ≥ 100,000/mcL (stable off any growth factor within 4 weeks of first&#xD;
                  study treatment administration)&#xD;
&#xD;
               -  Hemoglobin ≥8.5 g/dl (transfusion to achieve this level is not permitted within 2&#xD;
                  weeks of first study treatment administration)&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except&#xD;
                  participants with Gilbert's Syndrome who must have normal direct bilirubin)&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤ 2.0 x IULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt;2.5 x ULN&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x ULN or creatinine clearance &gt; 40 mL/min by&#xD;
                  Cockcroft-Gault&#xD;
&#xD;
               -  Albumin ≥ 3 g/dL&#xD;
&#xD;
               -  INR and aPTT &lt;1.5 x IULN (This applies only to patients who do not receive&#xD;
                  therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such&#xD;
                  as low-molecular-weight heparin or warfarin, should be on a stable dose).&#xD;
&#xD;
               -  CK ≤ 1.5 X ULN&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to&#xD;
             the start of study treatment.&#xD;
&#xD;
          -  Women must not be breastfeeding.&#xD;
&#xD;
          -  WOCBP must agree to follow instructions for method(s) of contraception for the&#xD;
             duration of treatment with study treatment(s) and for a total of 10 months&#xD;
             post-treatment completion.&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
          -  Consent for fresh pre-treatment, on-treatment, biopsy samples at acceptable clinical&#xD;
             risk, as judged by the investigator.&#xD;
&#xD;
          -  Participants must be willing and able to comply with scheduled visits, treatment&#xD;
             schedule, and laboratory testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with immunotherapy for cancer&#xD;
&#xD;
          -  Known metastatic disease&#xD;
&#xD;
          -  Known invasive cancer in contralateral breast&#xD;
&#xD;
          -  Patients with a previous history of non-breast malignancy are eligible only if they&#xD;
             meet the following criteria for a cancer survivor:&#xD;
&#xD;
               -  Has undergone potentially curative therapy for all prior malignancies AND&#xD;
&#xD;
               -  Has been considered disease-free for at least 1 year (with the exception of basal&#xD;
                  cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix.&#xD;
&#xD;
          -  Currently receiving any other investigational agents.&#xD;
&#xD;
          -  Concomitant use of statins while on study (there is a 14-day washout). However, a&#xD;
             participant using statins for over 3 months prior to study drug administration and in&#xD;
             stable status without CK rise may be permitted to enroll.&#xD;
&#xD;
          -  A history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to paclitaxel, carboplatin, nivolumab, cabiralizumab, or other&#xD;
             agents used in the study. Known history of sensitivity to infusions containing Tween&#xD;
             20 (polysorbate 20) and Tween 80 (polysorbate 80).&#xD;
&#xD;
          -  Evidence of uncontrolled ongoing or active infection, requiring parenteral&#xD;
             anti-bacterial, anti-viral, or anti-fungal therapy ≤ 7 days prior to administration of&#xD;
             study treatment. Patients receiving prophylactic antibiotics (e.g., for prevention of&#xD;
             a urinary tract infection or chronic obstructive pulmonary disease) are eligible.&#xD;
&#xD;
          -  Patients with prior allogeneic bone marrow transplantation or prior solid organ&#xD;
             transplantation.&#xD;
&#xD;
          -  History or risk of autoimmune disease, including, but not limited to, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and&#xD;
             ulcerative colitis), vascular thrombosis associated with antiphospholipid syndrome,&#xD;
             Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome,&#xD;
             multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.&#xD;
&#xD;
               -  Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid&#xD;
                  replacement hormone may be eligible.&#xD;
&#xD;
               -  Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may&#xD;
                  be eligible.&#xD;
&#xD;
               -  Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with&#xD;
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis would&#xD;
                  be excluded) are permitted provided that they meet the following conditions:&#xD;
&#xD;
                    -  Patients with psoriasis must have a baseline ophthalmologic exam to rule out&#xD;
                       ocular manifestations&#xD;
&#xD;
                    -  Rash must cover less than 10% of body surface area (BSA)&#xD;
&#xD;
                    -  Disease is well controlled at baseline and only requiring low potency&#xD;
                       topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%,&#xD;
                       flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)&#xD;
&#xD;
                    -  No acute exacerbations of underlying condition within the last 12 months&#xD;
                       (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate,&#xD;
                       retinoids, biologic agents, oral calcineurin inhibitors; high potency or&#xD;
                       oral steroids)&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),&#xD;
             organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing&#xD;
             pneumonia, etc.), or evidence of active pneumonitis on screening chest computed&#xD;
             tomography (CT) scan.&#xD;
&#xD;
          -  Current or history of clinically significant muscle disorders (e.g., myositis,&#xD;
             fibromyalgia), recent unresolved muscle injury, or any condition known to elevate&#xD;
             serum CK levels.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  History of any chronic hepatitis as evidenced by the following:&#xD;
&#xD;
               -  Positive test for hepatitis B surface antigen&#xD;
&#xD;
               -  Positive test for qualitative hepatitis C viral load (by polymerase chain&#xD;
                  reaction [PCR]).&#xD;
&#xD;
          -  Positive test for latent tuberculosis (TB) at screening (e.g. T-SPOT or Quantiferon&#xD;
             test) or evidence of active TB.&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of&#xD;
             need for a major surgical procedure during the course of the study with the exception&#xD;
             of the planned breast cancer surgery that is part of the trial design. Participants&#xD;
             must have recovered from the effects of major surgery or significant traumatic injury&#xD;
             at least 14 days before the first dose of study treatment.&#xD;
&#xD;
          -  Any uncontrolled medical condition which, in the opinion of the Investigator, would&#xD;
             pose a risk to participant safety or interfere with study participation or&#xD;
             interpretation of individual participant results.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications (including, but not limited to,&#xD;
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor&#xD;
             necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1.&#xD;
&#xD;
               -  Patients who have received acute, low dose, systemic immunosuppressant&#xD;
                  medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.&#xD;
&#xD;
               -  The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone)&#xD;
                  for patients with orthostatic hypotension or adrenocortical insufficiency is&#xD;
                  allowed. The use of replacement doses of prednisone or other corticosteroid for&#xD;
                  adrenocortical insufficiency is allowed&#xD;
&#xD;
               -  Participants with a condition requiring systemic treatment with either&#xD;
                  corticosteroids (&gt; 10 mg daily prednisone equivalents) or other immunosuppressive&#xD;
                  medications within 14 days of start of study treatment. Inhaled or topical&#xD;
                  steroids and adrenal replacement steroid doses &gt; 10 mg daily prednisone&#xD;
                  equivalent are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
          -  Evidence of coagulopathy or bleeding diathesis.&#xD;
&#xD;
          -  Ascites needing paracentesis or medical management.&#xD;
&#xD;
          -  Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this&#xD;
             study, but HIV-positive patients must have:&#xD;
&#xD;
               -  A stable regimen of highly active anti-retroviral therapy (HAART)&#xD;
&#xD;
               -  No requirement for concurrent antibiotics or antifungal agents for the prevention&#xD;
                  of opportunistic infections&#xD;
&#xD;
               -  A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard&#xD;
                  PCR-based tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Davis, M.D.</last_name>
    <phone>314-273-3581</phone>
    <email>aadavis@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Davis, M.D.</last_name>
      <phone>314-273-3581</phone>
      <email>aadavis@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Davis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Welbaecher, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Aft, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark A Watson, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David DeNardo, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingqin (Rosy) Luo, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foluso Ademuyiwa, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nusayba Bagegni, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Bose, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Clifton, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Frith, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Ma, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Oppelt, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Peterson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Rearden, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caron Rigden, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

